Figure 3 — Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML

Navigate

Research Paper|Volume 12, Issue 7|pp. 5792–5811

Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML

Back to articleFigure 3(3 of 8)

100%

Figure 3.Kaplan–Meier curves associated with overall survival within age arms (60-66 vs 67-74 vs ≥ 75 years).

Figure 3 — Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML | Aging